Hillevax
IPOXOMA Royalty – A biotech royalty aggregator
Public · Boston, United States · Founded 2021 · $136.3M raised
- Headquarters
- Boston, Massachusetts
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- hillevax.com
- Total Funding
- $136.3M
- Last Round
- $135.0M Series DSep 2021
- Rounds
- 2
- Type
- Public
About
HilleVax is a clinical-stage biopharmaceutical company focused on developing vaccines. Lead program HIL-214 is a bivalent VLP vaccine candidate for moderate-to-severe acute gastroenteritis from norovirus in infants. Founded 2021, HQ Boston. Raised $136M. Phase 2b trial showed limited efficacy 2024. Website now redirects to XOMA Royalty.
Summary
Hillevax is a Biotech company based in Boston, United States, founded in 2021. It has raised $136.3M in total across 2 rounds, most recently a $135.0M Series D round in Sep 2021. Investors include Frazier Healthcare, Takeda (JP) and Lightspeed VP.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2022
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...